Aduro Biotech, Inc. (ADRO) VP Sells $39,091.43 in Stock

Aduro Biotech, Inc. (NASDAQ:ADRO) VP Blaine Templeman sold 3,557 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $10.99, for a total transaction of $39,091.43. Following the sale, the vice president now directly owns 65,275 shares in the company, valued at $717,372.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Aduro Biotech, Inc. (NASDAQ:ADRO) remained flat at $11.20 during trading on Friday. The company’s stock had a trading volume of 2,170,865 shares. The company’s market cap is $835.65 million. The stock has a 50 day moving average price of $11.61 and a 200-day moving average price of $10.97. Aduro Biotech, Inc. has a 52 week low of $8.75 and a 52 week high of $15.52.

Aduro Biotech (NASDAQ:ADRO) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The company had revenue of $5.90 million for the quarter, compared to analysts’ expectations of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. Aduro Biotech’s revenue for the quarter was down 84.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.03 earnings per share. Equities analysts forecast that Aduro Biotech, Inc. will post ($1.37) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Aduro Biotech, Inc. (ADRO) VP Sells $39,091.43 in Stock” was published by Equities Focus and is the sole property of of Equities Focus. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.equitiesfocus.com/2017/09/17/aduro-biotech-inc-adro-vp-sells-39091-43-in-stock.html.

A number of research firms have weighed in on ADRO. Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. BidaskClub cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Zacks Investment Research cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Cowen and Company began coverage on shares of Aduro Biotech in a research report on Tuesday, July 18th. They set an “outperform” rating for the company. Finally, HC Wainwright set a $18.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $19.00.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP boosted its position in shares of Aduro Biotech by 9.1% during the 1st quarter. Wellington Management Group LLP now owns 9,448,529 shares of the biotechnology company’s stock worth $101,571,000 after purchasing an additional 791,770 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Aduro Biotech by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock worth $28,637,000 after purchasing an additional 129,079 shares in the last quarter. State Street Corp boosted its position in shares of Aduro Biotech by 8.3% during the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock worth $7,808,000 after purchasing an additional 52,597 shares in the last quarter. Northern Trust Corp boosted its position in shares of Aduro Biotech by 15.1% during the 2nd quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock worth $5,166,000 after purchasing an additional 59,490 shares in the last quarter. Finally, Baillie Gifford & Co. boosted its position in shares of Aduro Biotech by 45.8% during the 2nd quarter. Baillie Gifford & Co. now owns 422,700 shares of the biotechnology company’s stock worth $4,819,000 after purchasing an additional 132,700 shares in the last quarter. Institutional investors own 35.05% of the company’s stock.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply